Bevacizumab biosimilar (Zydus Cadila)

贝伐珠单抗生物类似药 (Zydus Cadila)

Report date: 2023/01/10 17:36:27

Base Information

Drug NameBevacizumab biosimilar (Zydus Cadila)
Drug Alias NameMAb3贝伐人源化单抗生物仿制药 (Zydus Cadila)贝伐赛珠单抗生物仿制药 (Zydus Cadila)贝伐珠单抗生物仿制药 (Zydus Cadila)贝伐单抗生物仿制药 (Zydus Cadila) +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsMetastatic breast cancerUterine Cervical NeoplasmsFallopian Tube Neoplasms +[9] 
Global Approved IndicationsMetastatic breast cancerUterine Cervical NeoplasmsFallopian Tube Neoplasms +[9] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2017/01/01
Country/TerritoryIndia
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesZydus Cadila
China Registration ClassN/A

Develop Information

Active CompaniesZydus Cadila
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerUterine Cervical NeoplasmsFallopian Tube Neoplasms +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XC07
Related LinksN/A